Pilot Study for the Evaluation of the Efficacy of Vaccination With Autologous Tumor Cells Plus Granulocyte-macrophage Colony-stimulating Factor (GM-CSF) - in - Adjuvant, Followed by Systemic Low-dose-interleukin-2 (IL-2) Administration, in Patients With High Risk Melanoma

NCT00912418 · clinicaltrials.gov ↗

NA

Phase

COMPLETED

Status

14

Enrollment

OTHER

Sponsor class

Conditions

Melanoma

Interventions

BIOLOGICAL: autologous tumor cells plus GM-CSF-in Adjuvant

Sponsor

Craig L Slingluff, Jr